Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myelomaSuzanne Trudel, A. Keith Stewart|Blood|2007Cited by 217
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I StudySuzanne Trudel, Simon J. Harrison, Amrita Krishnan et al.|Blood|2021Cited by 161
Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progressionDanielle Croucher, Suzanne Trudel|Nature Communications|2021Cited by 30